Newsby HottubFor agents

Health

FDA flags rare vision-loss risk with GLP-1 drugs; doctors say patients need not panic

223 outletsin 17 languages and 26 countriesFirst reported , latest

The FDA has mandated that safety labels for GLP-1 drugs include a warning about the potential risk of a rare eye condition known as NAION[1, 3–6, 9]. NAION, often referred to as an "eye stroke," occurs when blood flow to the optic nerve is reduced[1, 6]. The FDA issued this warning to ensure patients are aware of the potential risk, although the risk appears small and data is mixed[5, 6]. The FDA's action follows reports and studies indicating a possible link between GLP-1 drugs and vision loss[2–8, 10].

A language model wrote this brief from the reports below; the numbers link to them. Check the reports for anything that matters.

Told around the world

People and organizations

Named in this story's headlines. Add any of them to CRM by Hottub; nothing is saved until you press Add there.

Every report 300 reports

  1. 《TAIPEI TIMES》 GLP-1 weight-loss drugs can cause blindness in rare cases, FDA warns

    FDA warns that GLP-1 weight-loss drugs can cause blindness in rare cases.

    news.ltn.com.twTW

    Add to CRM
  2. GLP-1 ilaçları için yeni bir görme kaybı uyarısı yayınlandı

    New warning about vision loss for GLP-1 drugs

    HabertürkTR

    Add to CRM
  3. FDA, GLP1 kilo verme ilaçları için körlük riski uyarısında bulundu

    FDA warns of blindness risk for GLP1 weight loss drugs

    TRT HaberTR

    Add to CRM
  4. FDA traži da GLP-1 lijekovi imaju upozorenje o mogućoj trajnoj sljepoći

    FDA requests that GLP-1 drugs have a warning about possible permanent blindness

    TelegramHR

    Add to CRM
  5. Rare eye condition associated with GLP-1s

    National Community Pharmacists AssociationUS

    Add to CRM